On Wednesday, Optimi Health (OPTH.US) commenced trading on the U.S. stock market, with its share price opening more than 13% lower at $6.10. The IPO price was set at $7.05. Optimi Health is a Canadian pharmaceutical company primarily focused on producing MDMA and psilocybin-based drug products for mental health treatment. The company is headquartered in British Columbia, Canada, and operates a GMP-certified drug manufacturing facility licensed by Health Canada.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.